Novo Nordisk is launching its weight loss pill Wegovy in the United Arab Emirates, the Danish drugmaker said Wednesday, marking its first launch outside the U.S. market. Novo’s approach will be guided by patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure, said Emil Kongshøj Larsen, executive vice president,…
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the…
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 8% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity. In…
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker…
Novo Nordisk shares received a much-needed end of the year boost as the Wegovy maker became the first drugmaker to secure approval of a GLP-1 pill for weight loss, in what one analyst called a “redemption for the investors” after the stock’s worst year ever. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s…
The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in…
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the…
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Shares of Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease. The company on Friday…
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Wegovy-maker Novo Nordisk said Wednesday that it was doubling down on direct-to-consumer sales as it contends with copycat compounders and Washington’s demands for lower domestic drug prices. Chief Financial Officer Karsten Munk Knudsen…
